IMAGEENS has developed Europe’s first clinically-validated software as a medical device enabling the measurement of MRI imaging biomarkers recognized as a major risk factor for cardiovascular diseases and significant predictors of mortality. Our software as a medical device has successfully received the notoriously challenging class 2a approval under the EU’s new Medical Device Regulation (EU MDR).
Enabling the measurement of predictive imaging biomarkers
of death and hard cardiovascular events
Based on a robust, clinically
validated platform
IMAGEENS has developed a clinical decision tool based on ArtFun+’s biomarkers for cardiovascular check-ups. IT helps cardiologist and clinics to start and monitor cardiovascular prevention by providing a personal report that screen the cardiovascular age and detect the earliest signs of CV disease based on our proprietery data.e
We share our knowledge & approach with leading healthcare institutions to build more Predictive Clinical Decision AI